Published on 6 Jun 2022 on Zacks via Yahoo Finance

Boston Scientific (BSX) Gains from New Buyouts, FX Issue Ails

Boston Scientific Corporation BSX has been gaining from its slew of strategic acquisitions and product launches. However, mounting operating expenses and foreign exchange headwinds raise apprehension. The stock currently carries a Zacks Rank #3 (Hold).

Over the past year, Boston Scientific has outperformed the industry it belongs to. The stock has lost 3.3% against the industry’s 22.9% fall.

Boston Scientific ended the first quarter of 2022 on a bullish note, with adjusted earnings and revenues surpassing the Zacks Consensus Estimate. Total operational sales grew 13% versus the prior year, while organic sales grew 10% above the high end of the company guidance. The company’s performance was strong across all regions where most of its businesses grew at or faster than their respective markets.First-quarter performance in the United States was particularly strong in WATCHMAN, PI, cardiology and endoscopy. In Europe, Middle East, Africa, the company grew 12% year over year on operational basis, with particular strength in structural heart, including TAVR, WATCHMAN and other interventional cardiology therapies, as well as electrophysiology. In Asia-Pac, Boston Scientific grew 14% operationally, with new product launches fueling the growth in the region, notably, POLARx and Ranger in Japan, and WaveWriter Alpha in Australia.